Study of MRG007 for advanced solid tumors
Part of Cancer, Digestive system, Hormones & metabolism clinical trials.
This trial tests a new drug called MRG007 for people with advanced solid tumors that haven't responded to other treatments. The drug targets a protein called CDH17 on cancer cells; you need a tumor sample to check for it.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be willing to sign an informed consent form and follow the study plan.
- Your doctor expects you to live at least 3 more months.
- You need a tumor sample to test for CDH17, or you must be willing to have a biopsy to get one.
- You must have advanced or metastatic cancer that has not responded to standard treatments, you couldn't tolerate them, or there are no standard options left.
- You need to have at least one tumor that can be measured on a scan.
- Your daily activity level must be fairly good (able to take care of yourself and do light work).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called MGC026 that targets a protein called B7-H3 on cancer cells, aiming to shrink or slow different advanced solid tumors. It is an early-phase study to find the right dose and check safety.
This trial is testing a new oral medication, VVD-133214, for people with advanced solid tumors that have a specific genetic feature called MSI-high or dMMR. The study will see if the drug is safe and effective when given alone or with other drugs like bevacizumab or pembrolizumab.
This trial tests a new drug called DM002 for people with advanced solid tumors that have not responded to standard treatments. The drug targets two proteins (MUC1 and HER3) found on some cancer cells, and may help shrink tumors or slow their growth.
This trial tests a new drug, MRG007, combined with other treatments for advanced colorectal cancer. The goal is to see if this combination can shrink tumors or slow the cancer's growth when standard treatments have not worked.
This trial tests a new drug, MRG006A, for people with advanced solid tumors, especially liver cancer. It aims to see if the drug is safe and effective by targeting a protein called GPC3 found on some cancer cells.
This trial tests a drug called MRG003 for people with certain advanced cancers that have a specific protein, EGFR. The drug targets the cancer cells that have this protein, which may help stop the cancer from growing.
Hear when a new Locally Advanced or Metastatic Solid Tumors trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.